- Home
- EDTK vs EDSA Comparison
EDTK vs EDSA Comparison
Compare EDTK & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- EDSA
- Stock Information
- Founded
- EDTK 2013
- EDSA 2015
- Country
- EDTK China
- EDSA Canada
- Employees
- EDTK N/A
- EDSA N/A
- Industry
- EDTK Other Consumer Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- EDSA Health Care
- Exchange
- EDTK Nasdaq
- EDSA Nasdaq
- Market Cap
- EDTK 14.3M
- EDSA 15.9M
- IPO Year
- EDTK 2020
- EDSA N/A
- Fundamental
- Price
- EDTK $0.99
- EDSA $2.11
- Analyst Decision
- EDTK
- EDSA Strong Buy
- Analyst Count
- EDTK 0
- EDSA 2
- Target Price
- EDTK N/A
- EDSA $13.00
- AVG Volume (30 Days)
- EDTK 6.7K
- EDSA 38.0K
- Earning Date
- EDTK 08-18-2025
- EDSA 08-08-2025
- Dividend Yield
- EDTK N/A
- EDSA N/A
- EPS Growth
- EDTK N/A
- EDSA N/A
- EPS
- EDTK N/A
- EDSA N/A
- Revenue
- EDTK $893,690.00
- EDSA N/A
- Revenue This Year
- EDTK N/A
- EDSA N/A
- Revenue Next Year
- EDTK N/A
- EDSA N/A
- P/E Ratio
- EDTK N/A
- EDSA N/A
- Revenue Growth
- EDTK N/A
- EDSA N/A
- 52 Week Low
- EDTK $0.80
- EDSA $1.55
- 52 Week High
- EDTK $1.21
- EDSA $5.18
- Technical
- Relative Strength Index (RSI)
- EDTK 56.65
- EDSA 42.63
- Support Level
- EDTK $0.86
- EDSA $2.02
- Resistance Level
- EDTK $1.05
- EDSA $2.35
- Average True Range (ATR)
- EDTK 0.06
- EDSA 0.14
- MACD
- EDTK 0.00
- EDSA -0.03
- Stochastic Oscillator
- EDTK 47.14
- EDSA 18.00
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.